Jaguar Health, Inc.

Equities

JAGX

US47010C7065

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 17/05/2024 BST			5-day change	1st Jan Change
0.2585 ^USD	-9.84%		-11.50%	+70.74%

05-17	Jaguar Health Plans 1-for-60 Reverse Split Next Week	MT
05-14	Earnings Flash (JAGX) JAGUAR HEALTH Reports Q1 Revenue $2.4M, vs. Street Est of $3M	MT

Jaguar Health, Inc. Announces Appointment of Pravin Chaturvedi as Chief Scientific Officer and Chair of the Scientific Advisory Board

April 06, 2022 at 03:44 pm

Jaguar Health, Inc. announced that Pravin Chaturvedi, PhD, a pharmaceutical veteran and leading clinical development expert, has been appointed Chief Scientific Officer and Chair of the Scientific Advisory Board of Jaguar. Prior to this appointment, Dr. Chaturvedi served as Chair of the company's SAB and Acting CSO of Jaguar and Napo Pharmaceuticals (Napo), Jaguar's wholly owned subsidiary.

Latest news about Jaguar Health, Inc.

Jaguar Health Plans 1-for-60 Reverse Split Next Week	05-17	MT
Earnings Flash (JAGX) JAGUAR HEALTH Reports Q1 Revenue $2.4M, vs. Street Est of $3M	05-14	MT
Transcript : Jaguar Health, Inc., Q1 2024 Earnings Call, May 14, 2024	05-14
Jaguar Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Jaguar Health Applies for Investigational New Animal Drug Status for Potential Dog Diarrhea Treatment	05-06	MT
Jaguar Health, Inc. Establishes New Investigational New Animal Drug File with the Center for Veterinary Medicine of the U.S. Food and Drug Administration	05-06	CI
Venture Life renews revolving credit facility with Santander and HSBC	04-19	AN
Jaguar Health, Inc. Appoints Catherine Miller Collis to the Role of Senior Vice President of Growth Strategy	04-18	CI
Wall Street Set to Open Sharply Lower Wednesday as Inflation Rises More Than Expected	04-10	MT
Exchange-Traded Funds Down, Equity Futures Higher Pre-Bell Wednesday Ahead of Fed Meeting Minutes	04-10	MT
Top Premarket Gainers	04-10	MT
Jaguar Health, Inc. Appoints Massimo Radaelli, PhD, as President of Jaguar International	04-03	CI
Transcript : Jaguar Health, Inc., Q4 2023 Earnings Call, Apr 01, 2024	04-01
Jaguar Health, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
Jaguar Health Reaches Agreement With FDA on Design, Conduct of Medicine Study	02-15	MT
Jaguar Health, Inc. Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea in Dogs	02-15	CI
Top Premarket Gainers	01-26	MT
Napo Pharmaceuticals, Inc. Announces Majority of Subjects in Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Continue on to Stage II	12-11	CI
FDA Approves Renewal of Canalevia-CA1, Jaguar Health?s Drug for Chemotherapy-Induced Diarrhea in Dogs	12-04	CI
Jaguar Health, Inc. announced that it has received $0.06 million in funding	11-29	CI
Sector Update: Health Care Stocks Higher Late Tuesday Afternoon	11-21	MT
Sector Update: Health Care Stocks Rise Tuesday Afternoon	11-21	MT
Jaguar Health's Napo Pharmaceuticals Awaits Data on Phase 3 Trial of Crofelemer; Shares Fall	11-21	MT
Transcript : Jaguar Health, Inc., Q3 2023 Earnings Call, Nov 14, 2023	11-14
Jaguar Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI

Chart Jaguar Health, Inc.

Duration

Period

More charts

Company Profile

Jaguar Health, Inc. is a commercial-stage pharmaceuticals company. The Company is focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. It operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. The Canalevia-CA1 is for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Its subsidiary Napo Pharmaceuticals, Inc. focuses on developing and commercializing human prescription pharmaceuticals.

Sector

Biotechnology & Medical Research

Calendar

21/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.2585 USD

Average target price

0.6 USD

Spread / Average Target

+132.11%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
JAGUAR HEALTH, INC.	+70.74%	71.4M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-2.65%	21.96B
BIONTECH SE	-14.15%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs